Results for tag: "Acid Sphingomyelinase Deficiency Drug"

The Acid Sphingomyelinase Deficiency Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disorder that affects the body's ability to break down a type of fat called sphingomyelin. ASMD can lead to a variety of symptoms, including neurological and pulmonary complications. Treatment of ASMD typically involves enzyme replacement therapy, which is the administration of a drug that contains the missing enzyme. The Acid Sphingomyelinase Deficiency Drug market is a relatively small market, but it is growing as more treatments become available. Companies in the market are focused on developing new treatments and improving existing ones. Some of the companies in the market include Sanofi, Pfizer, and Shire. Show Less Read more